BTIG Reiterates Buy Rating on Bicara Therapeutics, Sets $39 Target
BTIG reiterated its Buy rating and $39 price target for Bicara Therapeutics. The target implies 132.4% upside from the Oct. 16 close of $16.78.
Story updates
10:07:35 AM UTC
SquawkNews
Bicara Therapeutics Price Target Maintained With a $39.00/Share by BTIG